

CITATION REPORT

List of articles citing

Sentinel node biopsy after neoadjuvant treatment in breast cancer: Five-year follow-up of patients with clinically node-negative or node-positive disease before treatment

DOI: 10.1016/j.ejso.2015.11.019

European Journal of Surgical Oncology, 2016, 42, 361-8.

Source: <https://exaly.com/paper-pdf/65377827/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
108	Limiting Axillary Surgery for Patients with Initial Biopsy-Proven Axillary Metastases After Preoperative Chemotherapy: To Clip or Not to Clip?. 2016 , 23, 3432-3434		1
107	Overexploring and overtreating the axilla. 2017 , 31, 290-294		9
106	Breast conserving surgery and locoregional control after neoadjuvant chemotherapy. <i>European Journal of Surgical Oncology</i> , 2017 , 43, 865-874	3.6	8
105	Swedish prospective multicenter trial on the accuracy and clinical relevance of sentinel lymph node biopsy before neoadjuvant systemic therapy in breast cancer. 2017 , 163, 93-101		11
104	The efficacy of WGA modified daunorubicin anti-resistant liposomes in treatment of drug-resistant MCF-7 breast cancer. 2017 , 25, 541-553		9
103	Swedish prospective multicenter trial evaluating sentinel lymph node biopsy after neoadjuvant systemic therapy in clinically node-positive breast cancer. 2017 , 163, 103-110		21
102	Comparative study between ultrasound-guided fine needle aspiration cytology of axillary lymph nodes and sentinel lymph node histopathology in early-stage breast cancer. 2017 , 13, 3299-3302		3
101	Long-Term Follow-Up of Node-Negative Breast Cancer Patients Evaluated via Sentinel Node Biopsy After Neoadjuvant Chemotherapy. 2017 , 17, 644-649		14
100	Tumor Biology Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients Presenting with Locally Advanced Breast Cancer. 2017 , 24, 3896-3902		30
99	[Sentinel lymph node biopsy and neoadjuvant treatment in breast cancer]. 2017 , 104, 892-901		2
98	PIK3CA oncogenic mutations in neoadjuvant treatments for breast cancer. 2017 , 11, 519-521		
97	Outcome following sentinel lymph node biopsy-guided decisions in breast cancer patients with conversion from positive to negative axillary lymph nodes after neoadjuvant chemotherapy. 2017 , 166, 473-480		21
96	Current approach of the axilla in patients with early-stage breast cancer. 2017 ,		27
95	Sentinel node biopsy after primary chemotherapy in cT2 N0/1 breast cancer patients: Long-term results of a retrospective study. <i>European Journal of Surgical Oncology</i> , 2017 , 43, 2012-2020	3.6	17
94	Management of the Axilla. 2017 , 357-363		
93	Neoadjuvant systemic treatment for breast cancer in Italy: The Italian Society of Surgical Oncology (SICO) Breast Oncoteam survey. <i>European Journal of Surgical Oncology</i> , 2018 , 44, 1157-1163	3.6	4
92	Surgical management of the axilla in early breast cancer. 2018 , 55, 47-65		3

91	Management of the Axilla: Sentinel Lymph Node Biopsy. 2018 , 275-284		
90	Sentinel lymph node biopsy management after neoadjuvant treatment for breast cancer care. 2018 , 14, 1423-1426		5
89	Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?. 2018 , 25, 1488-1494		56
88	Sentinel node biopsy for axillary management after neoadjuvant therapy for breast cancer: a single-center retrospective analysis with long follow-up. 2018 , 48, 87-94		1
87	Axilläre Operationen im Wandel der Zeit. 2018 , 51, 744-751		
86	Current Status and Future Perspectives of Axillary Management in the Neoadjuvant Setting. 2018 , 13, 337-341		7
85	The Evolution of the Current Indications for Sentinel Lymph Node Biopsy in Breast Cancer. 2018 , 90, 186-194		1
84	Breast cancer metastasis through the lympho-vascular system. 2018 , 35, 443-454		15
83	Neoadjuvant chemotherapy for breast cancer-background for the indication of locoregional treatment. 2018 , 194, 797-805		10
82	Decreasing Use of Axillary Dissection in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. 2018 , 25, 2596-2602		35
81	Tailoring breast cancer therapies to reduce mortality and improve quality of life: San Antonio Breast Cancer Symposium 2017 (part 2). 2018 , 14, 1893-1896		
80	Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer with axillary node metastasis: A survey of clinical practice. 2019 , 42, 314-319		2
79	Surgical Management of the Axilla in Clinically Node-Positive Patients Receiving Neoadjuvant Chemotherapy: A National Cancer Database Analysis. 2019 , 26, 3517-3525		20
78	The Basics of Sentinel Lymph Node Biopsy: Anatomical and Pathophysiological Considerations and Clinical Aspects. 2019 , 2019, 3415630		11
77	Sentinel node biopsy after primary systemic therapy in node positive breast cancer patients: Time trend, imaging staging power and nodal downstaging according to molecular subtype. <i>European Journal of Surgical Oncology</i> , 2019 , 45, 969-975	3.6	12
76	Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. 2019 , 26, 3846-3855 ¹⁰		
75	Validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: Preliminary results. 2019 , 30, 52-57		19
74	Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2019 , 30, 1194-1220		528

73	Highlights of the 16th St Gallen International Breast Cancer Conference, Vienna, Austria, 20-23 March 2019: personalised treatments for patients with early breast cancer. 2019 , 13, 924	13
72	Clinical impact of sentinel lymph node biopsy after neoadjuvant systemic treatment in luminal B, HER-2 positive and triple-negative breast cancer patients with initially involved axillary lymph node(s) : Protocol for prospective, non-randomised, observational clinical trial. 2019 , 29-34	
71	News in surgery of patients with early breast cancer. 2019 , 48 Suppl 1, S2-S6	2
70	Standard and controversies in sentinel node in breast cancer patients. 2019 , 48 Suppl 1, S53-S56	8
69	Targeted axillary dissection in breast cancer by marking lymph node metastasis with a magnetic seed before starting neoadjuvant treatment. 2019 , 2019, rjz344	11
68	Does Lymph Node Status Prior to Neoadjuvant Chemotherapy Influence the Number of Sentinel Nodes Removed?. 2019 , 26, 336-342	5
67	Twenty-five years of change in the management of the axilla in breast cancer. 2020 , 26, 22-26	7
66	Breast and axillary surgery in malignant breast disease: a review focused on literature of 2018 and 2019. 2020 , 32, 91-99	4
65	Enhancing the Critical Role of Core Needle Biopsy in Breast Cancer. 2020 , 92, 76-84	
64	Axillary surgery in breast cancer: An updated historical perspective. 2020 , 47, 341-352	15
63	Leveraging Neoadjuvant Chemotherapy to Minimize the Burden of Axillary Surgery: a Review of Current Strategies and Surgical Techniques. 2020 , 12, 317-325	
62	ASO Author Reflections: Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy for Node-Positive Breast Cancer: Is It Oncologically Safe?. 2020 , 27, 707-708	0
61	Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer. 2020 , 15, 608-618	3
60	Avoiding Axillary Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy in Breast Cancer: Rationale for the Prospective, Multicentric EUBREAST-01 Trial. 2020 , 12,	10
59	Patterns of Failure in Women Who Have Residual Nodal Disease After Neoadjuvant Chemotherapy for Breast Cancer According to Extent of Lymph Node Surgery. 2020 , 20, 431-438	0
58	Selecting Node-Positive Patients for Axillary Downstaging with Neoadjuvant Chemotherapy. 2020 , 27, 4515-4522	24
57	ASO Author Reflections: Axillary Staging in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy-Beyond Clinical Trials. 2020 , 27, 4523-4524	1
56	Progress in Local Treatment of Breast Cancer: A Narrative Review. 2020 , 42, 356-364	0

55	Axillary management for patients with breast cancer after neoadjuvant chemotherapy: Results of a survey among Brazilian breast surgeons. 2020 , 122, 1247-1251		2
54	Predictive factors for omitting lymphadenectomy in patients with node-positive breast cancer treated with neo-adjuvant systemic therapy. 2020 , 26, 888-896		2
53	Long-term prognosis in breast cancer is associated with residual disease after neoadjuvant systemic therapy but not with initial nodal status. <i>British Journal of Surgery</i> , 2021 , 108, 583-589	5.3	3
52	Leveraging the increased rates of pathologic complete response after neoadjuvant treatment in breast cancer to de-escalate surgical treatments. 2021 , 123, 71-79		3
51	Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer: guiding a more selective axillary approach. 2021 , 186, 527-534		8
50	Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 804-812	3.6	38
49	Oncologic Safety of Sentinel Lymph Node Biopsy Alone After Neoadjuvant Chemotherapy for Breast Cancer. 2021 , 28, 2621-2629		11
48	ASO Author Reflections: Low Rates of Axillary Recurrence in Clinically Node-Positive Breast Cancer Patients Undergoing Sentinel Lymph Node Biopsy Alone Following Pathologic Response to Neoadjuvant Chemotherapy. 2021 , 28, 2630-2631		
47	Axillary Management After Neoadjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer. 2021 , 28, 1358-1367		10
46	Second Reply to: "Metaplastic Breast Carcinoma and Other Triple-Negative Subtype Breast Cancers: Which is the Worst?". 2021 , 28, 811-812		
45	Sentinel Node Biopsy after Neoadjuvant Chemotherapy for Breast Cancer: Preliminary Experience with Clinically Node Negative Patients after Systemic Treatment. 2021 , 11,		1
44	Lymph nodal radiotherapy in breast cancer: what are the unresolved issues?. 2021 , 21, 827-840		1
43	Sentinel node biopsy alone for breast cancer patients with residual nodal disease after neoadjuvant chemotherapy. 2021 , 11, 9056		1
42	Prognosis according to clinical and pathologic lymph node status in breast cancer patients who underwent sentinel lymph node biopsy alone after neoadjuvant therapy. 2021 , 16, e0251597		0
41	Evolving Trends in Surgical Management of Breast Cancer: An Analysis of 30 Years of Practice Changing Papers. 2021 , 11, 622621		0
40	Feasibility and validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: Definitive results. 2021 , 38, 101636		1
39	Axillary Lymph Node Dissection Rates and Prognosis From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer. 2021 , 11, 741120		
38	Development of a predictive score of axillary lymph node dissection based on targeted axillary dissection in patients with breast cancer diagnosis, affected lymph nodes, and neoadjuvant treatment. 2021 , 38, 101629		1

37	Favorable outcome with sentinel lymph node biopsy alone after neoadjuvant chemotherapy in clinically node positive breast cancer at diagnosis: Turkish Multicentric NEOSENTI-TURK MF-18-02-study. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 2506-2514	3.6	2
36	Predictors of positive axillary non-sentinel lymph nodes in breast cancer patients with positive sentinel lymph node biopsy after neoadjuvant systemic therapy. 2021 , 163, 128-135		1
35	Feasibility and reliability of sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patients with positive axillary nodes at initial diagnosis: An up-to-date meta-analysis of 3,578 patients. 2021 , 59, 256-269		1
34	Carbon tattooing for targeted lymph node biopsy after primary systemic therapy in breast cancer: prospective multicentre TATTOO trial. <i>British Journal of Surgery</i> , 2021 , 108, 302-307	5.3	13
33	Predictors of Nodal Pathological Complete Response in Asian Women with Stage II-III Node-Positive Breast Cancer. 2021 , 99, 359-364		1
32	Sentinel Node Biopsy alone or with Axillary Dissection in Breast Cancer Patients after Primary Chemotherapy: Long-term Results of a Prospective Interventional Study. 2020 ,		8
31	Feasibility of radioguided occult lesion localization of clip-marked lymph nodes for tailored axillary treatment in breast cancer patients treated with neoadjuvant systemic therapy. 2019 , 9, 94		8
30	Locoregional Management After Neoadjuvant Chemotherapy. 2020 , 38, 2281-2289		14
29	Sentinel node biopsy in conservative surgery for breast cancer: a changing role in clinical practice. 2020 , 75, 386-391		1
28	Axillary management after neoadjuvant treatment. 2020 , 75, 400-407		1
27	The Adventure of Axillary Treatment in Early Stage Breast Cancer. 2020 , 16, 1-15		3
26	Extended Sentinel Node Biopsy in Breast Cancer Patients who Achieve Complete Nodal Response with Neoadjuvant Chemotherapy. 2020 , 16, 99-105		2
25	AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update. 2021 , 81, 1112-1120		2
24	Lymphfem. 2019 , 235-243		
23	Quelle est la valeur prédictive de l'imagerie pour évaluer la réponse axillaire après chimiothérapie néoadjuvante des cancers mammaires avec envahissement axillaire. 2018 , 28, 215-225		
22	Locally Advanced Breast Cancer. 2019 , 365-374		
21	Axillary Surgery and Other Regional Lymph Nodes. 2019 , 289-298		
20	Axillary surgery in breast cancer: evolution and de-escalation. 2020 , 75, 383-385		1

- 19 Sentinel Lymph Node Metastasis on Clinically Negative Patients: Preliminary Results of a Machine Learning Model Based on Histopathological Features. **2021**, 11, 10372 2
- 18 Therapiealgorithmen für das Mammakarzinom. **2021**, 27, 1165-1174
- 17 Sentinel Lymph Node Biopsy in Breast Cancer Patients With Pathological Complete Response in the Axillary Lymph Node After Neoadjuvant Chemotherapy.. **2021**, 24, 531-541 0
- 16 Questions of axillary region surgery in breast cancer patients after systemic neoadjuvant therapy. **2022**, 17, 56-65
- 15 AGO-Empfehlungen zur operativen Therapie der Axilla nach neoadjuvanter Chemotherapie: Update 2021. **2022**, 19, 56-64
- 14 Axillary Management: How Has Neoadjuvant Chemotherapy Changed Our Surgical Approach?. **2022**, 14, 1-7
- 13 Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol.. **2022**, 193, 37 1
- 12 Surgical Considerations and Expectations in Patients Receiving Neoadjuvant Chemotherapy and Neoadjuvant Endocrine Therapy. **2022**, 219-238
- 11 De-escalating axillary surgery in early-stage breast cancer.. **2021**, 0
- 10 Surgery after Neoadjuvant Chemotherapy: A Clip-Based Technique to Improve Surgical Outcomes, a Single-Center Experience.. **2022**, 14, 0
- 9 Regional Nodal Management After Preoperative Systemic Therapy. **2022**, 32, 228-236 0
- 8 Axillary surgery after neoadjuvant therapy in initially node-positive breast cancer: international EUBREAST survey. *British Journal of Surgery*, 5:3 0
- 7 Multidisciplinary considerations in the management of breast cancer patients receiving neoadjuvant chemotherapy. **2022**, 101191
- 6 Accurate Evaluation of Feature Contributions for Sentinel Lymph Node Status Classification in Breast Cancer. **2022**, 12, 7227 0
- 5 Is the Platelet-Lymphocyte Ratio a Useful Tool for Predicting Sentinel Lymph Node Metastasis in Breast Cancer Patients Receiving Neoadjuvant Therapy?. 0
- 4 This house believes that: Sentinel node biopsy alone is better than TAD after NACT for cN+ patients. **2023**, 67, 21-25 2
- 3 The Oncologic Safety of Sentinel Lymph Node Biopsy in Patients with Node-Positive Breast Cancer with Complete Response to Neoadjuvant Chemotherapy: A Single-Center Experience. **2023**, 2023, 1-7 0
- 2 Breast cancer and clinically negative status after neoadjuvant chemotherapy. 32, 0

- 1 Targeted axillary dissection using Radioguided Occult Lesion Localization technique in the clinically negative marked lymph node after neoadjuvant treatment in breast cancer patients. **2023**, o